Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical Applications and Protocols

PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical... The detection of lesions in the context of biochemical recurrence of prostate cancer is a major challenge for all imaging modalities. Recently, the prostate-specific membrane antigen (PSMA) is recognized as a novel target for the PET–CT (positron emission tomography–computed tomography) imaging of prostate cancer with the tracer 68Ga-PSMA (68Gallium-labelled PSMA), mainly in the detection of relapses and metastasis. PSMA PET–CT imaging shows high tracer uptake at the sites of primary tumor and lymph node, and bone metastasis in direct correlation with aggressiveness and Gleason scores. PSMA PET–CT seems to be a highly accurate imaging tool for restaging of prostate cancer patients with biochemical recurrence, and it proved to be clearly superior in detecting prostate cancer lesions at low PSA levels when compared to other methods. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Radiology Reports Springer Journals

PET–CT with (68 Ga)Gallium-Labeled PSMA Ligand for the Diagnosis of Prostate Cancer: Clinical Applications and Protocols

Loading next page...
 
/lp/springer-journals/pet-ct-with-68-ga-gallium-labeled-psma-ligand-for-the-diagnosis-of-s0AUyac8an

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Imaging / Radiology
eISSN
2167-4825
DOI
10.1007/s40134-016-0189-1
Publisher site
See Article on Publisher Site

Abstract

The detection of lesions in the context of biochemical recurrence of prostate cancer is a major challenge for all imaging modalities. Recently, the prostate-specific membrane antigen (PSMA) is recognized as a novel target for the PET–CT (positron emission tomography–computed tomography) imaging of prostate cancer with the tracer 68Ga-PSMA (68Gallium-labelled PSMA), mainly in the detection of relapses and metastasis. PSMA PET–CT imaging shows high tracer uptake at the sites of primary tumor and lymph node, and bone metastasis in direct correlation with aggressiveness and Gleason scores. PSMA PET–CT seems to be a highly accurate imaging tool for restaging of prostate cancer patients with biochemical recurrence, and it proved to be clearly superior in detecting prostate cancer lesions at low PSA levels when compared to other methods.

Journal

Current Radiology ReportsSpringer Journals

Published: Oct 28, 2016

There are no references for this article.